Can Dance Therapy Improve Motor Learning in Parkinson’s Disease (PD)?


In order to find the most effective rehabilitative therapies for Parkinsonian patients, the present study is aimed to evaluate whether, in a multidisciplinary intensive rehabilitation treatment, the dance therapy, applied to the motor learning, promote additional benefits.

Full Title of Study: “Can Dance Therapy Improve Motor Learning in Parkinson’s Disease?”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Investigator)
  • Study Primary Completion Date: June 1, 2018


  • Behavioral: Dance Therapy
    • the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing
  • Behavioral: exercises without dance
    • the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing

Arms, Groups and Cohorts

  • Experimental: dance thrapy
    • 4-week Multidisciplinary Rehabilitation Treatment + Dance Therapy Treatment (2 hours par week)
  • Active Comparator: exercises without dance
    • 4-week Multidisciplinary Rehabilitation Treatment + Exercises without music (2 hours par week)

Clinical Trial Outcome Measures

Primary Measures

  • Timed Up and Go Test (TUG)
    • Time Frame: 4 weeks
    • To determine fall risk and measure the progress of balance, sit to stand, and walking.

Secondary Measures

  • 6 Minutes Walking Test (6MWT)
    • Time Frame: 4 weeks
    • The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
  • Balance Berg Scale (BBS)
    • Time Frame: 4 weeks
    • to objectively determine a patient’s ability (or inability) to safely balance during a series of predetermined tasks.

Participating in This Clinical Trial

Inclusion Criteria

  • Stage 2.5-3 according to the Hoehn and Yahr scale (H&Y);
  • Stable pharmacological treatment for the last 6 weeks before the enrolment and during the hospitalization;

Exclusion Criteria

  • Any focal brain lesion detected in brain imaging studies (CT or MRI) performed in the previous 12 months;
  • Drug-induced dyskinesias;
  • Disturbing resting and/or action tremor, corresponding to scores 2-4 in the specific items of UPDRS III;
  • Behavioral disturbances (evaluated with Neuropsychiatric Inventory);
  • Visual and auditory dysfunctions according to the general clinical evaluation and medical history;
  • cognitive decline (MMSE correct score < 24)

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ospedale Generale Di Zona Moriggia-Pelascini
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Giuseppe Frazzitta, MD, Principal Investigator, Department of Parkinson’s disease, Movement Disorders and Brain Injury Rehabilitation, “Moriggia-Pelascini” Hospital – Via Pelascini, 3, 22015, Gravedona ed Uniti, Como, Italy
  • Overall Contact(s)
    • Paola Ortelli, PsyD, 3332974872,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.